Jean Bosco Mbonimpa

Mr. Jean Bosco Mbonimpa

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
SFSandra Noukimi Fankem
Sandra Noukimi Fankem
Jean Bosco MbonimpaJean Bosco Mbonimpa
Jean Bosco Mbonimpa
EKEdgar Mutebwa Kalimba
Edgar Mutebwa Kalimba
MDMariama Telly Diallo
Mariama Telly Diallo
MEMary Teke Efeti
Mary Teke Efeti
Jacob SouopguiJacob Souopgui
Jacob Souopgui
Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment in Rwanda, but the emergence of drug resistance threatens their efficacy. This study conducted genomic surveillance of Plasmodium falciparum isolates collected in Kigali between October 2021 and June 2023 to assess resistance markers. Using Oxford Nanopore Technology and Sanger sequencing methods, we analyzed 250 clinical isolates focusing on mutations in the pfcrt, pfmdr1, pfdhfr, pfdhps, and Pfkelch13 genes. Resistance-associated mutations were highly prevalent: pfcrt 76T (26%) and pfmdr1 184F (72.8%) were common, indicating continued lumefantrine pressure. All isolates carried mutations in pfdhfr and pfdhps, with the IRNI-SAEAA and IRNI-SAEGA haplotypes found in 45.6% and 24.8% of samples, respectively, suggesting sustained antifolate resistance. Pfkelch13 mutations were present in 50.4% of isolates, including validated R561H (25.6%), A675V and candidate P441L mutations. Novel haplotypes, including K189T + R561H (24.8%), were identified for the first time in Rwanda. The BTB/POZ domain mutation H384R was observed in 6.4% of isolates, raising questions about its potential functional role. These findings highlight complex and evolving resistance patterns and emphasize the urgent need for continued molecular surveillance and functional validation to inform malaria control strategies in Rwanda.

Verified
Journal Article
Open access
PDF file
Ndoricyimpaye Ella LarissaNdoricyimpaye Ella Larissa
Ndoricyimpaye Ella Larissa
JSJacques Van Snick
Jacques Van Snick
Jean de Dieu NIYOYITAJean de Dieu NIYOYITA
Jean de Dieu NIYOYITA
PKPhilbert Kanimba
Philbert Kanimba
Jean Bosco MbonimpaJean Bosco Mbonimpa
Jean Bosco Mbonimpa
NRNadine Rujeni
Nadine Rujeni
The proper control of Plasmodium infection requires a finely balanced immune response. Here, we evaluated the implication of TGF-β1 and TGF-β3 in this process using novel monoclonal antibodies to measure their plasma concentrations in comparison with other cytokines and the expression of FOXP3 mRNA. Plasma cytokine levels were measured in 80 patients with severe anaemic malaria and 186 with a mild presentation using ELISA, and rtPCR was used to measure FOXP3 mRNA expression. While no mature TGF-β isoforms were detected in the plasma, the latent TGF-β1 and TGF-β3 were strongly upregulated in patients with mild malaria and nearly undetected in patients with severe disease. Similar selective upregulation in mild patients was observed for IL-9 and FOXP3 mRNA, while IL-7, IL-10, IL-17, and IL-27, although higher in mild cases, were also detected in severe disease. In contrast, a clearly skewed trend of severe cases towards higher pro-inflammatory (IL-6, IL-13, TNF-α) and Th1 (IFN-γ) responses was observed, which was associated with a higher level of parasitaemia as well as lower IgG and higher IgM responses. Together, these results suggest that the stimulation of regulatory T cells through TGF-β1/TGF-β3 and IL-9 is paramount to an effective and balanced protective immunity in natural human malaria infection.

Verified
Journal Article
Open access
PDF file
EKEdgar Mutebwa Kalimba
Edgar Mutebwa Kalimba
SFSandra Noukimi Fankem
Sandra Noukimi Fankem
Jean Bosco MbonimpaJean Bosco Mbonimpa
Jean Bosco Mbonimpa
Cabirou Mounchili ShintouoCabirou Mounchili Shintouo
Cabirou Mounchili Shintouo
Radouane OUALIRadouane OUALI
Radouane OUALI
Jacob SouopguiJacob Souopgui
Jacob Souopgui
Malaria remains a significant public health challenge, particularly in endemic regions. The extensive genetic diversity of Plasmodium falciparum (Pf) complicates outbreak prediction and transmission control. One of its most polymorphic markers, merozoite surface protein 2 (MSP2), presents a potential target for molecular surveillance. This cross-sectional study, conducted at King Faisal Hospital Rwanda (KFHR) from October 2021 to June 2023, assessed MSP2’s utility in malaria prediction. PfMSP2 was sequenced, and selected amplicons were cloned, expressed in bacteria, and purified. These antigens were tested against sera from malaria patients and geographically diverse healthy individuals, with complementary surveys contextualizing serological findings. Of the 75 processed monoallelic clinical isolates, 3D7 strains predominated over FC27. Three MSP2-derived biomarkers were produced, eliciting significantly low IgG responses in malaria patients and Belgian controls, but a complex pattern emerged in healthy individuals, with significant differences between Rwandan and Cameroonian samples. IgG3 was the predominant subclass in individuals with high IgG responses. Notably, Rwandan individuals with weak humoral responses to the tested antigens but also other with high responses experienced malaria episodes in the subsequent year. These findings highlight MSP2 polymorphism as a valuable tool for malaria surveillance and outbreak prediction. Integrating genotyping and serology could enable precise, community-specific malaria risk assessments, strengthening control strategies.

25 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
Jacob SouopguiJacob Souopgui
Jacob Souopgui
SFSandra Noukimi Fankem
Sandra Noukimi Fankem
Jean Bosco MbonimpaJean Bosco Mbonimpa
Jean Bosco Mbonimpa
EKEdgar Mutebwa Kalimba
Edgar Mutebwa Kalimba
YKYvan Karuke
Yvan Karuke
MDMariama Diallo
Mariama Diallo
Malaria remains a major public health threat, particularly in sub-Saharan Africa. In Rwanda, Artemether-Lumefantrine (AL; Coartem) has been the primary treatment for uncomplicated malaria, though its efficacy is increasingly in question. Using clinical data and Plasmodium biobanks from King Faisal Hospital Kigali, we analyzed 23 selected samples from patient with recurrent malaria. Genotyping confirmed recrudescence rather than reinfection. Following the initial AL treatment, 56.5% (microscopy) and 83.3% (qPCR) remained positive, with symptoms persisting. After a second treatment, positivity declined but was still notable. Sequencing analysis revealed widespread MDR1 Y184F mutations and cumulative Pfkelch13 mutations, including H384R in the BTB/POZ domain, associated with treatment failure. Four failing strains lacked kelch13 mutations, indicating alternative resistance mechanisms. These findings support the need for expanded genetic surveillance to preserve ACT efficacy.